Home > Healthcare > Pharmaceuticals > Finished Drug Form > Vaginitis Therapeutics Market

Vaginitis Therapeutics Market Trends

  • Report ID: GMI7213
  • Published Date: Oct 2023
  • Report Format: PDF

Vaginitis Therapeutics Market Trends

  • The increasing cases of vaginitis is a significant driver for the growth of the market. For instance, according to National Center for Biotechnology Information (NCBI), vaginitis is one of the most common reasons for women to visit their primary care providers in the U.S., responsible for 10 million office visits annually. This larger patient pool creates a market need for various therapeutics, including prescription medications, over the counter drugs, and medical devices designed to treat or manage vaginitis.

Further, as the number of individuals diagnosed with vaginitis increases, the demand for treatments rises correspondingly. Therefore, the growing prevalence can lead to an increase in clinical trials and research studies. These studies explore new treatment options, contributing to the overall growth and advancement of the market.

  • While these therapeutics offer potential benefits, the associated antibiotic resistance possesses a challenge. With increase in resistance, the number of effective medications available for treating vaginitis diminishes. This limitation in treatment options can result in prolonged infections, more severe symptoms, and increased healthcare costs due to the need for alternative, often more expensive treatments, thereby hampering the market growth to certain extent.
Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Vaginitis therapeutics industry size was USD 3.6 billion in 2022 and is expected to reach USD 7.3 billion by 2032 due to the rising prevalence of vaginal infections, growing awareness pertaining to women’s health and the increasing availability of effective treatments worldwide.

The bacterial vaginosis disease type segment held 43.6% share of the vaginitis therapeutics industry in 2022 and is expected to register a significant CAGR from 2023-2032 on account of it being the most prevalent vaginal infection among women of reproductive age.

North America vaginitis therapeutics industry is expected to grow at 7.3% CAGR from 2023-2032 owing to a high prevalence of menopausal and postmenopausal women in the region.

Pfizer, Inc., Merck & Co., Novartis AG, Bayer AG, Lupin Pharmaceuticals, Inc., Sanofi SA, Dr. Reddy’s Laboratories Ltd, Sun Pharmaceuticals Pvt Ltd, Cipla Ltd, and Takeda Pharmaceuticals, are some of the major market worldwide.

Vaginitis Therapeutics Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 11
  • Tables & Figures: 316
  • Countries covered: 9
  • Pages: 170
 Download Free Sample